1 Senior Consultant, Department of Pathology, Max Super Specialty Hospital, New Delhi, India.
2 Professor, Department of Anesthesia, AIIMS, New Delhi, India.
World Journal of Advanced Research and Reviews, 2025, 27(01), 1609-1617
Article DOI: 10.30574/wjarr.2025.27.1.2661
Received on 02 June 2025; revised on 13 July 2025; accepted on 16 July 2025
Background: In scenario of scant data literature, this study was conducted for progesterone receptor as future hormone therapy in prostate lesions especially prostate cancer.
Introduction: Prostate cancer as leading cause of mortality, progesterone receptor to be envisaged as future adjunct hormone therapy to reduce morbidity and mortality of prostate. Carcinoma prostate being heterogenous disease, not much is known about biological behaviour of Progesterone receptors.
Material and methods: 40 cases of prostate, BHP, BHP with prostatitis, HGPIN and Adenocarcinoma were included where expressions of Progesterone receptors was carried out immunohistochemically.
Conclusion: PR analysed as Good prognostic marker, can be authenticated as future adjunct hormone therapy, More Studies required to authenticate it, Our study has been adjunct to that
PR (progesterone receptors); ER (Estrogen receptors); IHC (immunohistochemistry); BHP (benign hyperplasia prostate); ADC (Adenocarcinoma); HGPIN (High grade prostatic intraepithelial neoplasia)
Preview Article PDF
Babita Sodhi and Jyotsna Punj. Immunohistochemical analysis of Progesterone receptors in all Prostatic lesions, Case series study of 40 cases and review of Literature. World Journal of Advanced Research and Reviews, 2025, 27(1), 1609-1617. Article DOI: https://doi.org/10.30574/wjarr.2025.27.1.2661